Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabielsoin (CBE) is a non-psychoactive cannabinoid produced biosynthetically by Xinteza. It is a naturally occurring compound found in *Cannabis sativa*, where it primarily exists as a metabolite of cannabidiol (CBD). Xinteza utilizes a proprietary yeast-based biosynthesis platform to manufacture high-purity CBE for use as an active pharmaceutical ingredient (API). While the specific pharmacological profile of CBE is less extensively studied than major cannabinoids like THC or CBD, it is investigated for its potential interactions with the endocannabinoid system. Xinteza's business model focuses on the production and licensing of these rare cannabinoids as raw ingredients for pharmaceutical research and development rather than internal clinical development for specific therapeutic indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabielsoin.